Akumin — Debt Investor Presentation (October 2023)
65 slides from Akumin's debt investor presentation, Oct 20, 2023
Slide 1: Project Aperture Lender Presentation
Project Aperture Lender Presentation Akumin Inc. August 2023 Strictly Confidential and Trade Secret For Discussion Purposes Only
Slide 2: Table of Contents
Table of Contents Introduction to Stonepeak Operational Value-Add Plan Stonepeak Investment Thesis Recent Financial Performance Review Appendix Transaction Overview Supplementary Financial Materials Strictly Confidential and Trade Secret
Slide 3: Introduction to Stonepeak
Introduction to Stonepeak Strictly Confidential and Trade Secret
Slide 4: Stonepeak Key Highlights
Stonepeak Key Highlights Stonepeak is a leading global infrastructure and real assets-focused private equity firm with an 11-year investing history of delivering differentiated outcomes Independent & Global Platform Deep Sector Expertise $57.1bn Assets under Management1 $12.0bn In executed co-invest
Slide 5: Stonepeak's Global Footprint
Stonepeak’s Global Footprint Stonepeak is a leading global real assets manager with a comprehensive and complementary range of infrastructure funds across major geographies Latin America 3 investments to date North America 38 investments to date 146 total employees North America 38 investments to da
Slide 6: Hands-on Approach to Operational Value-Add
Hands-on Approach to Operational Value-Add Integrated Partnership Approach to Asset Management Stonepeak Portfolio Operations Process Stonepeak Deal Team Lead 02 Ultimate ownership and responsibility for all 01 Data Flow and Data aspects of success of an investment Integrity is Key Portfolio Frequen
Slide 7: Demonstrated Track Record of Operational Improvement
Demonstrated Track Record of Operational Improvement Focus on driving cost optimization and incremental margin growth John Steen Stonepeak Operating Partner, Former CEO of Paradigm, Current CEO of WTG Dan Walsh Bill Fathers Will Schleier Current CEO of TRAC Stonepeak Senior Advisor, Former Investmen
Slide 8: Business Development / Revenue Initiatives
Business Development / Revenue Initiatives Focus on both top-line growth and quality of revenue Increased Asset Utilization / Customer Wins Increased Revenue Visibility 54% $260.0 increase 1,500 975 $150.5 Conversion of $107.5 New Customer “Spot” Pool $73.5 3x Wins on Growing Revenue to increase $10
Slide 9: Comprehensive, Multi-Faceted Strategy to Drive Growth
Stonepeak Employs a Comprehensive, Multi-Faceted Strategy to Drive Growth, Including Continued Reinvestment Case study on following page Completed / Targeted Operational Strategy Selected Stonepeak Bolster Management Team / Manage Construction / Business Development / Investments Processes Build-Out
Slide 10: Platform Creation / Bolt-On M&A
Platform Creation / Bolt-On M&A Partnering with high-quality management teams to consolidate fragmented sectors into high-quality portfolios Installed MW Ramp (Inclusive of Signed Deals Only) Lineage Capacity (MM Cu. Ft.) Stonepeak 197 Stonepeak 700 70% of current Lineage creates capacity acquired s
Slide 11: Operational Value-Add Plan
Operational Value-Add Plan Strictly Confidential and Trade Secret
Slide 12: Core Framework for Akumin Partnership
Core Framework for Akumin Partnership Opportunity to leverage operational expertise and access to capital to complete business transformation at Akumin In our view, timely consummation of the proposed transaction at this juncture provides necessary liquidity and expertise for value-maximizing operat
Slide 13: Key Operating Theme: Volume Capture
Key Operating Theme: Volume Capture Keys to Volume Growth Increase volume from Maximize schedule & ensure Have the right people referrers and patients seamless patient experience at the right place at the right time to provide high-quality care Process to sustained value Growing same-store volumes i
Slide 14: Day Plan – Key Areas of Operational Focus
180 Day Plan – Key Areas of Operational Focus Stonepeak has identified key operating advisors to help guide transformation initiatives Key Workstreams Financial Operating Technology and Human Resources Reporting Cadence Platform Integration Managed Care / Account and Churn Compensation Customer Sale
Slide 15: Stonepeak Investment Thesis
Stonepeak Investment Thesis Strictly Confidential and Trade Secret
Slide 16: Stonepeak Investment Thesis
Stonepeak Investment Thesis Sector tailwinds identified in 2021 are proving out; however, we believe operational overhaul and discipline are required for Akumin to capture its share of market growth Thematic Opportunity 1 Healthcare volumes services growing: o Aging and expanding population o Preven
Slide 17: Organic Growth Tailwinds – Radiology
1 Organic Growth Tailwinds – Radiology Freestanding radiology sector volumes continue to benefit from secular volume tailwinds Aging Population MRI Pricing (Hospital vs Freestanding Locations) (% of Population)1 ($ per Scan)2 Key sources driving greater Radiology procedures: 2-3x cheaper at freestan
Slide 18: Organic Growth Tailwinds – Oncology
1 Organic Growth Tailwinds – Oncology Radiation oncology sector is experiencing similar volume expansion dynamics Overview U.S. Cancer Cases over Time # of New Cancer Cases (000’s)1 Cancer cases and treatments continue to increase: o Aging population o Growing chronic illnesses correlated to cancer
Slide 19: Organic Growth Tailwinds – AKU Performance vs. RDNT
1 Organic Growth Tailwinds – AKU Performance vs. RDNT Same-Store Volume Growth Comparison (2Q 2023 YoY Same-Store Growth %) MRI PET / CT CT Routine Imaging Overall 19% 17% 16% 16% 11% 8% 9% 7% 6% 7% 4% 5% 4% 2% 2% 3% NA N/A (0%) (1%) (3%) (4%) (6%) (5%) (23%) Akumin RDNT Mobile Fixed ADG Total Rad R
Slide 20: Platform Scale Benefits
1 2 Platform Scale Benefits Broad geographic reach combined with diverse offerings affords commercial opportunities Akumin’s Broad Geographic Footprint1 States with CON Legislation2 State with Radiology Locations CON Program Radiology & Oncology Locations Oncology Locations (Only) 48 states and 180
Slide 21: Platform Scale Benefits
1 2 Platform Scale Benefits Despite these advantages, we believe AKU has not unlocked its full commercial potential ’21 and ’22 AKU New Radiology Revenue by Source Capitated Contracts and Hospital Pricing Relationships (% of Total New Revenue in ’21 and ’22)1 RDNT Imaging Revenue Breakout Capitated
Slide 22: Consolidation Opportunity
1 3 Consolidation Opportunity Akumin remains a natural consolidator in the fragmented outpatient imaging space Highly Fragmented Market1 Akumin Historical Annual M&A2 Reduction given shuttering of Existing Sites ~6% unprofitable sites New Sites in Given Year 205 ~3% 180 79 <3% 126 124 2 ~80-85% 84 4
Slide 23: Recent Financial Performance Review
Recent Financial Performance Review Strictly Confidential and Trade Secret
Slide 24: Historical Revenue – Pro Forma Combined Company
Historical Revenue – Pro Forma Combined Company (adj. for Disc. Ops.) Modest topline growth (excl. discontinued ops) since 2019 FY2019A to FY2023E Bridge Pro Forma Revenue ($mm)1 790 Revenue (incl. Disc. Ops) 747 +29 750 +5 2 751 742 75 Disc. Ops +41 +3 19 (8 ) (3 ) 59 (32 ) (0 ) 749 Revenue from 72
Slide 25: Pricing vs. Volume Decomposition
Pricing vs. Volume Decomposition (excl. Discontinued Operations) Despite challenged operating backdrop, topline (excl. Disc. Ops.) has grown 1.2% L5YE Pro Forma (Combined Company) Historical Revenue Decomposition1 Year 2019 2020 2021 2022 20232 CAGR (‘19—‘23) MRI Volumes (000’s) 878.5 778.5 864.6 87
Slide 26: Historical EBITDA – Pro Forma Combined Company
Historical EBITDA – Pro Forma Combined Company FY2019A to FY2023E Bridge Pro Forma EBITDA excl. Disc. Ops ($mm)1 EBITDA 22.3% 24.7% 20.3% 19.2% 16.6% Margin % EBITDA incl. Fixed site business key driver of margin deterioration (see 159 168 146 Disc. Ops cost breakout on page 29) – Stonepeak believes
Slide 27: 2023 Monthly vs. Prior Year
2023 Monthly vs. Prior Year Q1 tracked ahead of ’22; however, weak April / June performance driving overall YoY declines Revenue January February March April May June Monthly Q1 revenue slight beat 2022 $56.9 $58.2 $71.1 $64.1 $61.6 $66.5 over prior year % of FY22 7.6% 7.8% 9.5% 8.5% 8.2% 8.9% 2023
Slide 28: 2023 Performance: Revenue by Segment
2023 Performance: Revenue by Segment Mobile business continues to grow, while legacy Akumin fixed sites deteriorate 1H22A vs. 1H23A Commentary ($mm) Strong Mobile radiology revenue o Buoyed by strong market growth, % Change YoY (7.8%) (7.5%) +7.2% (5.5%) (1.6%) particularly in advanced PET / CT imag
Slide 29: 2023 Performance: EBITDA by Segment
2023 Performance: EBITDA by Segment 1H22A vs. 1H23A ($mm) % EBITDA 18.6% Margin 16.0% 70.2 1 3 2 +5.5 4 +2.8 59.7 (10.1 ) (6.4 ) (2.2 ) 1H22 Fixed ADG Mobile Oncology Corporate 1H23 FY22A vs. FY23E ($mm) 19.2% 16.6% 3 1 144.1 2 4 +4.6 +2.5 125.0 (20.7 ) (3.4 ) (2.1 ) FY22A Fixed ADG Mobile Oncology
Slide 30: 2023 Segment Review: Fixed Business
1 2023 Segment Review: Fixed Business Note: EBITDA metrics pre-Corporate EBITDA Bridge: 1H22A vs. 1H23A EBITDA Bridge: FY22A vs. FY23E ($mm) ($mm) % EBITDA % EBITDA 10.1% Margin 9.5% Margin (835 bps) (788 bps) margin margin 23.4 (19.4 ) 12.6 (9.1 ) (1.3 ) (1.0 ) (5.5%) 2.2% Revenue (7.8%) 1.2% Reven
Slide 31: 2023 Segment Review: ADG Business
2 2023 Segment Review: ADG Business Note: EBITDA metrics Normalization in collections (vs. 2022 highs) along with wages have hurt margin pre-Corporate EBITDA Bridge: 1H22A vs. 1H23A EBITDA Bridge: FY22A vs. FY23E Commentary ($mm) ($mm) 2022 saw elevated collection rates % EBITDA from recently acquir
Slide 32: 2023 Segment Review: Mobile Business
3 2023 Segment Review: Mobile Business Note: EBITDA metrics Same-store volume growth has driven topline and margin improvement in mobile pre-Corporate EBITDA Bridge: 1H22A vs. 1H23A EBITDA Bridge: FY22A vs. FY23E Commentary ($mm) ($mm) to offer Ability leading-edge PET / % EBITDA CT scans, in partic
Slide 33: 2023 Segment Review: Oncology Business
4 2023 Segment Review: Oncology Business Note: EBITDA metrics pre-Corporate EBITDA Bridge: 1H22A vs. 1H23A EBITDA Bridge: FY22A vs. FY23E Commentary ($mm) ($mm) Stonepeak believes a re-focus on business development is essential % EBITDA for Oncology business growth % EBITDA 37.1% 38.6% 37.9% Margin
Slide 34: Maintenance Capex
Maintenance Capex Adjusted for use of operating leases, maintenance capex remains consistent with prior years FY2019A to FY2023E Summary Pro Forma Revenue and Maintenance Capex ($mm)1 Revenue (excl. Disc. Ops) Maintenance Capex (excl. Disc. Ops)2 749 751 716 728 Capex 683 % of Sales 3.1% 3.1% 4.1% 2
Slide 35: Appendix
Appendix
Slide 36: Supplementary Financial Materials
Supplementary Financial Materials Strictly Confidential and Trade Secret
Slide 37: Akumin Earnings Summary ('22 vs '23)
Akumin Earnings Summary (‘22 vs ’23) Key P&L Metrics by Segment ($mm) Revenue 1H22 1H23 Var ($) Var (%) FY22 FY23 Var ($) Var (%) Fixed 125.2 115.4 (9.8) (7.8%) 245.3 231.9 (13.4) (5.5%) ADG 44.7 41.3 (3.3) (7.5%) 84.1 83.6 (0.5) (0.6%) Mobile 146.3 156.9 10.6 7.2% 295.4 314.3 18.9 6.4% Rad Total $3
Slide 38: Akumin Cost Breakout by Segment (1/2) – % of Revenue
Akumin Cost Breakout by Segment (1 / 2)—% of Revenue Costs as % of Revenue Fixed Costs as a % of Revenue 1H22 1H23 Var (bps) FY22 FY23 Var (bps) Labor 34.5% 36.5% 203 bps 34.3% 37.8% 345 bps Med Supplies 5.4% 8.0% 268 bps 5.7% 8.0% 236 bps Prof Services Fees 15.4% 18.3% 287 bps 16.3% 17.7% 140 bps R
Slide 39: Akumin Cost Breakout by Segment (2/2) – % of Revenue
Akumin Cost Breakout by Segment (2 / 2)—% of Revenue Costs as % of Revenue Mobile Costs as a % of Revenue 1H22 1H23 Var (bps) FY22 FY23 Var (bps) Labor 20.2% 19.7% (52 bps) 20.2% 19.9% (37 bps) Med Supplies 10.8% 13.9% 312 bps 11.3% 14.1% 280 bps Prof Services Fees 0.4% 0.5% 3 bps 0.4% 0.5% 4 bps Re
Slide 40: Akumin Cost Breakout by Segment (1/2) – Nominal
Akumin Cost Breakout by Segment (1 / 2) – Nominal Cost Breakout ($mm) Fixed Segment Cost Breakout 1H22 1H23 Var ($) Var (%) FY22 FY23 Var ($) Var (%) Labor 43.2 42.1 (1.0) (2.4%) 84.3 87.7 3.4 4.0% Med Supplies 6.7 9.3 2.6 38.2% 13.9 18.6 4.7 33.9% Prof Services Fees 19.3 21.1 1.8 9.4% 39.9 41.0 1.1
Slide 41: Akumin Cost Breakout by Segment (2/2) – Nominal
Akumin Cost Breakout by Segment (2 / 2) – Nominal Cost Breakout ($mm) Mobile Segment Cost Breakout 1H22 1H23 Var ($) Var (%) FY22 FY23 Var ($) Var (%) Labor 29.6 30.9 1.3 4.5% 59.8 62.5 2.7 4.4% Med Supplies 15.9 21.9 6.0 38.1% 33.3 44.2 10.9 32.9% Prof Services Fees 0.7 0.8 0.1 14.9% 1.2 1.4 0.2 17
Slide 42: 1H Results: Segment EBITDA Bridges
Note: EBITDA metrics 1H Results: Segment EBITDA Bridges pre-Corporate Fixed Segment ADG Segment ($mm) ($mm) 10.1% % EBITDA 46.7% Margin 20.9 Change from topline 34.9% 12.6 assuming constant costs 14.4 (3.3 ) (3.1 ) 2.2% 2.5 (9.8 ) (0.3 ) 1H22 Costs Other 1H23 1H22 Costs Other 1H23 Constant Change Co
Slide 43: FY23E Reforecast: Segment EBITDA Bridges
Note: EBITDA metrics FY23E Reforecast: Segment EBITDA Bridges pre-Corporate Fixed Segment ADG Segment ($mm) ($mm) % EBITDA 41.7% 9.5% 37.9% Margin Change from topline 35.1 23.4 assuming constant costs 31.7 (0.5 ) (2.9 ) 1.2% (13.4 ) 2.7 (7.2 ) FY22A Costs Other FY23E FY22A Costs Other FY23E Constant
Slide 44: 1H Results: Fixed & ADG Nominal Cost Breakout
Note: EBITDA metrics 1H Results: Fixed & ADG Nominal Cost Breakout pre-Corporate Fixed Segment Cost Breakout – 1H22A vs. 1H23A Nominal Change ($mm) 112.6 +2.6 +1.8 +1.3 +0.8 112.9 (0.5 ) (0.8 ) (2.2 ) (1.0 ) (1.6 ) 1H22 Labor Med Suppl. Prof. Fees Rent / IT Marketing Other Tractor Field Mgmt SG&A 1H
Slide 45: 1H Results: Mobile & Oncology Nominal Cost Breakout
Note: EBITDA metrics 1H Results: Mobile & Oncology Nominal Cost Breakout pre-Corporate Mobile Segment Cost Breakout – 1H22A vs. 1H23A Nominal Change ($mm) +6.0 +0.1 102.1 97.0 +1.3 (0.0 ) (0.0 ) (0.0 ) (1.5 ) (0.5 ) (0.3 ) 1H22 Labor Med Suppl. Prof. Fees Rent / IT Marketing Other Tractor Field Mgmt
Slide 46: FY23E Reforecast: Fixed & ADG Nominal Cost Breakout
Note: EBITDA metrics FY23E Reforecast: Fixed & ADG Nominal Cost Breakout pre-Corporate Fixed Segment Cost Breakout – FY22A vs. FY23E Nominal Change ($mm) +3% +4.7 +1.1 +2.4 +1.0 229.2 222.0 +3.4 (0.5 ) (1.2 ) (3.1 ) (0.5 ) FY22A Labor Med Suppl. Prof. Fees Rent / IT Marketing Other Tractor Field Mgm
Slide 47: FY23E Reforecast: Mobile & Oncology Nominal Cost Breakout
Note: EBITDA metrics FY23E Reforecast: Mobile & Oncology Nominal Cost Breakout pre-Corporate Mobile Segment Cost Breakout – FY22A vs. FY23E Nominal Change ($mm) +7% +10.9 +0.2 +0.0 +0.0 +0.3 +2.4 207.8 193.5 +2.7 (0.4 ) (1.9 ) FY22A Labor Med Suppl. Prof. Fees Rent / IT Marketing Other Tractor Field
Slide 48: FY23E Reforecast: Fixed & ADG Costs as % of Revenue
Note: EBITDA metrics FY23E Reforecast: Fixed & ADG Costs as % of Revenue pre-Corporate Fixed Segment Cost Breakout – FY22A vs. FY23E % of Revenue +2.4% +1.4% +1.8% +0.4% +0.3% 98.8% 90.5% +3.5% (0.2%) (0.0%) (1.2%) FY22A Labor Med Suppl. Prof. Fees Rent / IT Marketing Other Tractor Field Mgmt SG&A F
Slide 49: FY23E Reforecast: Mobile & Oncology Costs as % of Revenue
Note: EBITDA metrics FY23E Reforecast: Mobile & Oncology Costs as % of Revenue pre-Corporate Mobile Segment Cost Breakout – FY22A vs. FY23E % of Revenue 65.5% +2.8% +0.0% +0.0% +0.6% 66.1% (0.4%) (0.0%) (0.2%) (2.1%) (0.1%) FY22A Labor Med Suppl. Prof. Fees Rent / IT Marketing Other Tractor Field Mg
Slide 50: Important Information
Important Information This presentation is provided to you upon request on a confidential basis for discussion and informational purposes only to provide background information with respect to Stonepeak Partners LP (together, with its affiliates, “Stonepeak”) and its investment activities, in connec
Slide 51: Project Aperture Lender Follow Up
Project Aperture Lender Follow Up Akumin Inc. August 2023 Strictly Confidential and Trade Secret For Discussion Purposes Only
Slide 52: Executive Summary
Executive Summary Initial discussion on 8/21 resulted in specific follow-up items regarding historical performance and go-forward business plan Table of Contents Components of Value Creation 1 Decomposition of combined company earnings decline from ’19A – ’23E demonstrates key turnaround priorities
Slide 53: Key Components of EBITDA Deterioration
1 Key Components of EBITDA Deterioration Stonepeak has identified 5 key near-term addressable drivers of historical earnings declines FY19A – FY23E EBITDA 159.2 A B C D (5.5 ) E F (10.7 ) 125.0 (5.0 ) 2.0 (3.5 ) (11.6 ) Opportunity to reverse drivers A-D (est. +$30mm EBITDA visibility) Additional ne
Slide 54: Performance Improvement – Expected Quick Wins
Performance Improvement – Expected Quick Wins Initiatives below would be expected to be completed in the first 6 months1 of potential ownership Description / Details Potential Investment ($mm) A â–ª Selective management changes, including internal transfers from Ongoing Leadership Mobile team; new s
Slide 55: Performance Improvement – Medium / Longer Term Initiatives
Performance Improvement – Medium / Longer Term Initiatives Initiatives below would be expected to be completed after the first 6 months of potential ownership Description / Details Potential Investment ($mm) A â–ª Enterprise roll-out of remote operated command center for ROCC $0.3mm performing exams
Slide 56: Summary of Key IT Initiatives
Summary of Key IT Initiatives Stonepeak oversight and moderate investment required to complete IT projects in a timely manner Description / Details Estimated Completion Time1 Potential Investment ($mm) â–ª Roll-out following RIS features: online scheduling & registration, auto-reminders, virtual wai
Slide 57: Capex Spend: WholeCo Maintenance
Capex Spend: WholeCo Maintenance Adjusted for use of operating leases, maintenance capex remains consistent with prior years FY2019A to FY2023E Summary Pro Forma Revenue and Maintenance Capex ($mm)1 Revenue (excl. Disc. Ops) Maintenance Capex (excl. Disc. Ops)2 749 751 716 728 Capex 683 % of Sales 3
Slide 58: Capex Spend: Legacy Alliance
Capex Spend: Legacy Alliance 2023 capex on legacy Alliance segments also in-line with historical periods Legacy Alliance Historical Capex Summary Legacy Alliance Historical Capex 1H23A 1H23A Period 2019A 2020A 2021A 2022A Capex Op. Lease Adj. Capex Annualized Maintenance 9,023 8,082 8,194 11,258 4,3
Slide 59: Akumin Earnings Summary ('22 vs '23)
Akumin Earnings Summary (‘22 vs ’23) As noted previously, we believe fixed sites are key source of underperformance Key P&L Metrics by Segment ($mm) Revenue 1H22 1H23 Var ($) Var (%) FY22 FY23 Var ($) Var (%) Fixed 125.2 115.4 (9.8) (7.8%) 245.3 231.9 (13.4) (5.5%) ADG 44.7 41.3 (3.3) (7.5%) 84.1 83
Slide 60: 2023 Performance: EBITDA by Segment
2023 Performance: EBITDA by Segment Earnings either flat (-$0.3mm in revenue) or up (+$1.6mm) year-over-year, if exclude fixed segment 1H22A vs. 1H23A ($mm) % EBITDA 18.6% Margin 16.0% 70.2 +5.5 +2.8 59.7 (10.1 ) (6.4 ) (2.2 ) 1H22 Fixed ADG Mobile Oncology Corporate 1H23 FY22A vs. FY23E ($mm) 19.2%
Slide 61: 2023 Segment Review: Fixed Business
2023 Segment Review: Fixed Business To date, fixed sites have been treated almost entirely as a fixed cost business while volume opportunities were missed; we believe ability to drive variability in costs in near-term (e.g., in labor) is key as volume recovery efforts gain traction EBITDA Bridge: 1H
Slide 62: Fixed Cost Breakout (P&L View)
Fixed Cost Breakout (P&L View) Note: metrics pre-Corporate Fixed Site Costs Nominal Costs 1H22 1H23 Var ($) Var (%) FY22 FY23 Var ($) Var (%) Labor 43.2 42.1 (1.0) (2.4%) 84.3 87.7 3.4 4.0% Med Supplies 6.7 9.3 2.6 38.2% 13.9 18.6 4.7 33.9% Prof Services Fees 19.3 21.1 1.8 9.4% 39.9 41.0 1.1 2.6% Re
Slide 63: 1H Results: Fixed Site Cost Breakout
1H Results: Fixed Site Cost Breakout Note: metrics pre-Corporate Fixed Segment Cost Breakout – 1H22A vs. 1H23A Nominal Change ($mm) 112.6 +2.6 +1.8 +1.3 +0.8 112.9 (0.5 ) (0.8 ) (2.2 ) (1.0 ) (1.6 ) 1H22 Labor Med Suppl. Prof. Fees Rent / IT Marketing Other Tractor Field Mgmt SG&A 1H23 Fixed Segment
Slide 64: FY23E Reforecast: Fixed Site Cost Breakout
FY23E Reforecast: Fixed Site Cost Breakout Note: metrics pre-Corporate Fixed Segment Cost Breakout – FY22A vs. FY23E Nominal Change ($mm) +3% +4.7 +1.1 +2.4 +1.0 229.2 222.0 +3.4 (0.5 ) (1.2 ) (3.1 ) (0.5 ) FY22A Labor Med Suppl. Prof. Fees Rent / IT Marketing Other Tractor Field Mgmt SG&A FY23E Fix
Slide 65: Important Information
Important Information This presentation is provided to you upon request on a confidential basis for discussion and informational purposes only to provide background information with respect to Stonepeak Partners LP (together, with its affiliates, “Stonepeak”) and its investment activities, in connec